---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-23-000007"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:59:44.836507+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports Q4 2022 net loss $11.9M; cash runway extended through Q4 2024

## Summary
- Net loss $11.9M for Q4 2022, compared to $17.9M in Q4 2021; full year net loss $53.8M (2021: $50.0M).
- Cash and equivalents $129.3M at Dec 31, 2022; company drew down full $40M term loan, extending runway through at least Q4 2024.
- Collaboration revenue $7.3M (Q4 2022) from Jazz licensing agreement; zero in prior year period.
- Phase 1/1b WTX-124 (IL-2) dose-escalation ongoing; interim data expected in Q4 2023.
- First patient dosed in Phase 1 WTX-330 (IL-12) trial in Feb 2023; WTX-712 (IL-21) nominated for preclinical development.

## SEC filing metadata
- accession: 0001785530-23-000007
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/0001785530-23-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/howl-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-23-000007
- JSON: https://secwatch.observer/filing/0001785530-23-000007.json
- Plain text: https://secwatch.observer/filing/0001785530-23-000007.txt

## Key facts
- Earnings Releases
  Werewolf Therapeutics, Inc. updated its the fourth quarter and full year ended December 31, 2022 guidance (raised).
  - Period: the fourth quarter and full year ended December 31, 2022
  - Guidance: raised
  - Result: reported results
  source text: On March 23, 2023, Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing financial results for the quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/0001785530-23-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.